logo
Plus   Neg
Share
Email
Comment

Ind-Swift Labs Gets US FDA Nod For 5 APIs For Its Derabassi Facility

Pharma major Ind-Swift Laboratories Ltd. has obtained the US FDA nod for its five Active Pharmaceutical Ingredients or APIs manufactured at its Derabassi manufacturing facility.

The products for which the company has obtained the approval are Naratriptan Hydrochloride (anti-migraine), Ropinirole Hydrochloride (anti-Parkinson's disease), Donepezil Hydrochloride (anti-Alzheimer's disease), Acamprosate Calcium (anti-alcohol dependence) and Clarithromycin (Macrolide antibiotic).

With this approval, the company will be able to sell its products in the US market. The worldwide market for these products is $5 billion.

The company's Derabassi facility is already accredited by key accreditation agencies such as TGA, MHRA, COS, KFDA and PMDA.

Commenting on the development, Vice Chairman and Managing Director N.R. Munjal said, "This multi product approval will give multifold aggression to the sales as we have good presence in US through our US subsidiary and we expect this approval to give additional 50 percent to 60 percent growth in US sales."

At the BSE, Ind-Swift Laboratories closed Tuesday's trading at Rs.98.65, up 3.30 percent from the previous close.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
BlackRock Inc., the world's largest asset manager, said it plans to speak with gun makers and distributors following public outcry after the Florida high school shooting that killed 17 people. BlackRock, which had $6.3 trillion in assets under management as of December 31, 2017, holds shares in gun makers Sturm Ruger & Co. Inc. as well as American Outdoor Brands Corp. An upgraded boarding in Southwest Airline will cost you more. The airline usually not assign seats to passengers, but one can choose from an open seat. The Upgraded Boarding will allow passengers to choose from A1 - A15 boarding positions. The cost for these positions would be $30, $40 and $50, depending on flight and route. This option can be availed from the ticket counter or gate. Citigroup Inc.'s co-head of mergers and acquisitions, Peter Tague, is leaving the company, according to media reports, citing people familiar with the matter. Tague has been co-head of Global M&A business at Citigroup since March 2012, alongside Cary Kochman and Mark Shafir. It was not immediately clear what Tague intends to do after he leaves Citigroup.
comments powered by Disqus
Follow RTT